Financial Data and Key Metrics Changes - For Q1 2026, the company reported a net income of $30.8 million, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, Redemplo, approved for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [5][8] - Over 100 prescriptions for Redemplo have been received, with a balanced uptake across the U.S. [20] - The cardiometabolic pipeline includes ongoing studies for Zodasiran and new candidates ARO-INHBE and ARO-ALK7, with promising early results in weight loss and fat reduction [9][29] Market Data and Key Metrics Changes - The FDA approved Redemplo, marking a significant milestone for the company, with additional approvals from Health Canada and the Chinese National Medical Products Administration expected [8] - The company anticipates launching Redemplo in select EU countries and the U.K. later in 2026 [8] - The potential market for mixed hyperlipidemia, targeted by ARO-DimerPA, includes approximately 20 million people in the U.S. [11] Company Strategy and Development Direction - The company is focused on sustainable innovation and rational drug pricing, emphasizing the value offered to patients and healthcare systems [7] - Arrowhead aims to become cash flow positive and self-sustaining through multiple independent and partner launches, having completed transactions with gross proceeds of $1.33 billion [15][16] - The company is expanding its CNS portfolio with new delivery systems designed to penetrate the blood-brain barrier, targeting conditions like Alzheimer's disease [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to build on recent achievements and highlighted the potential for significant growth in 2026 and beyond [5][37] - The company expects key events in 2026, including commercial sales progress for Redemplo and readouts from phase III studies for plozasiran [37] - Management remains optimistic about the early feedback from payers and healthcare providers regarding Redemplo [21][57] Other Important Information - The company has strengthened its balance sheet significantly, with cash and investments totaling $917 million as of December 31, 2025 [34][35] - The company is not disclosing specific sales numbers for Redemplo until they become a meaningful driver of financials [32] Q&A Session Summary Question: Can you provide a breakdown of patient categories for Redemplo? - The majority of patients are from the APOC3 naive segment, with the remaining balance split roughly 50/50 between switch patients and those transitioning from the expanded access program [41][42] Question: What are the timelines for discussions with the FDA regarding obesity treatments? - Discussions with the FDA are expected around mid-year, and an IND filing is anticipated shortly thereafter [44] Question: What level of reduction in LDL-C and triglycerides are you looking for with ARO-DimerPA? - A reduction of around 40%-50% in both LDL and triglycerides would be encouraging for advancing the asset [46][47] Question: How are you thinking about potential pricing for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the company is still assessing the biology and potential efficacy of these candidates [50][51] Question: Can you discuss the pancreatitis event rates in ongoing trials? - The company is not providing additional details on event rates but acknowledges that events are being observed [53][54] Question: Has the pricing for Redemplo been discussed in relation to the SHTG market? - The focus is on ensuring coverage and access for high-risk patients, with discussions reflecting the clinical and economic value of Redemplo [56][59]

Financial Data and Key Metrics Changes - The company reported a net income of $30.8 million for Q1 2026, translating to an income of $0.22 per share, a significant improvement from a net loss of $173.1 million or a loss of $1.39 per share in Q1 2025 [31] - Revenue for the quarter totaled $264 million, primarily driven by licensing collaborations with Sarepta and Novartis, with approximately $229 million from the Sarepta collaboration [31][32] - Total operating expenses increased to approximately $223 million from $164 million in the prior year, driven by higher R&D and SG&A expenses [33] Business Line Data and Key Metrics Changes - The company launched its first commercial product, Redemplo, which received FDA approval as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS) [4][5] - Over 100 prescriptions for Redemplo have been received, with a balanced uptake across the U.S. and a significant proportion of patients enrolling in the patient support program [6][19] - The cardiometabolic pipeline includes ongoing studies for Zodasiran and new candidates ARO-INHBE and ARO-ALK7, with promising early data reported [9][10] Market Data and Key Metrics Changes - The company anticipates launching Redemplo in Canada and select EU countries later in 2026, with Sanofi marketing it in Greater China [8] - The U.S. market for mixed hyperlipidemia is estimated to include approximately 20 million people, representing a significant opportunity for the ARO-DimerPA candidate [11] Company Strategy and Development Direction - The company is focused on sustainable innovation and rational drug pricing, emphasizing the value of medicines to patients and healthcare systems [6] - Arrowhead aims to become cash flow positive and self-sustaining from commercial sales, with a strong emphasis on expanding its cardiometabolic and CNS portfolios [15][12] - The company has strengthened its balance sheet with $1.33 billion in gross proceeds from various transactions, enabling further development and commercialization efforts [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's position to build on recent achievements and highlighted the potential for significant revenue opportunities from upcoming product launches [4][17] - The company expects key events in 2026, including commercial sales progress for Redemplo and readouts from phase III studies for plozasiran, which could represent a $3-$4 billion opportunity [38] Other Important Information - The company has received breakthrough therapy designation for plozasiran, expediting its development for severe hypertriglyceridemia [25] - Arrowhead's proprietary TRiM platform is being utilized to enhance drug delivery across various tissues, including the CNS [12] Q&A Session Summary Question: Can you provide a breakdown of patient categories for Redemplo? - The majority of patients are from the APOC3 naive segment, with the remaining balance split roughly 50/50 between switch patients and those transitioning from the expanded access program [42][43] Question: What are the expectations for the obesity programs and FDA discussions? - Discussions with the FDA are expected around mid-year, and the company does not need all data from cohorts before determining the next steps [46] Question: What level of LDL-C and triglyceride reduction is expected for ARO-DimerPA? - A reduction of around 40%-50% in LDL and triglycerides would be encouraging for advancing the asset [48][49] Question: How is pricing being considered for ARO-INHBE and ARO-ALK7? - It is too early to speculate on pricing as the company is still assessing the biology and potential efficacy of these candidates [51] Question: What are the expectations for pancreatitis event rates in ongoing trials? - The company is not providing additional details on event rates but acknowledges that events are being observed [54] Question: How is payer feedback for Redemplo shaping discussions for SHTG? - Payer discussions are focused on ensuring coverage for high-risk patients, with a strong emphasis on the clinical and economic value of Redemplo [57][60]

Core Insights - Alnylam Pharmaceuticals has received European Commission approval for the label expansion of its RNAi therapeutic Amvuttra to treat wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy [1][9] - Year-to-date, Alnylam's stock has increased by 29.1%, significantly outperforming the industry, which has seen a decline of 0.9% [2] Approval Details - The European Commission's approval was based on positive results from the late-stage HELIOS-B study, where Amvuttra met all 10 pre-specified primary and secondary endpoints [3][9] - The HELIOS-B trial demonstrated statistically significant reductions in all-cause mortality and recurrent cardiovascular events, along with major improvements in functional capacity, health status, and heart failure symptoms [4][9] Competitive Advantage - Amvuttra is administered quarterly via subcutaneous injection, providing an advantage over existing therapies that require daily oral dosing [5] - The drug's novel RNAi mechanism allows for rapid knockdown of transthyretin (TTR), addressing the disease at its source [6] Market Impact - The approval in the EU follows similar approvals in the United States and Brazil, expanding Amvuttra's global footprint [6] - Alnylam reported better-than-expected first-quarter 2025 results, with revenue growth driven by increasing Amvuttra sales due to heightened patient demand [10][11]